Genie Fertility

Genie Fertility is a London-based reproductive health biotech company developing the world's first non-invasive diagnostic for uterine health. Founded in 2024 and emerging from stealth in October 2025, the company is tackling one of the most overlooked gaps in fertility medicine: the health of the uterus lining.

Infertility affects one in six couples globally, and IVF — the gold-standard treatment — fails 73% of the time. While significant research attention has been devoted to sperm quality, egg health, and embryo grading, the uterine environment has remained comparatively underexplored. The only existing clinical method to assess the endometrium is an invasive, expensive, and limited-accuracy biopsy. Genie Fertility is changing this by analysing menstrual blood — the monthly shedding of the entire uterine lining — which is rich in molecular biomarkers not present in a standard blood draw.

The company's machine learning discovery platform, trained on data from over 200,000 fertility patients, has identified novel predictive markers of uterine health in menstrual blood that correlate with implantation success and are addressable through existing medical interventions. Its first product is a non-invasive diagnostic test designed to be offered on day one of a patient's fertility journey, alongside standard workup, with the capacity to track change over time as medical interventions are applied.

Genie Fertility raised $1.22 million in a pre-seed round from Tiny VC, 33East VC, Arben Ventures, Transpose Platform, and Entrepreneur First in October 2025. The capital is funding a nine-month longitudinal clinical trial collecting data on pregnancy outcomes. The company works with leading IVF groups across the UK and Europe, and is advised by specialists from Imperial College London, Harvard Medical School, and the University of Melbourne. Beyond fertility, its platform has potential applications in PCOS, endometriosis, and perimenopause diagnostics.